Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
4.070
-0.010 (-0.25%)
At close: Oct 21, 2025, 4:00 PM EDT
4.070
0.00 (0.00%)
After-hours: Oct 21, 2025, 4:00 PM EDT
Organogenesis Holdings Revenue
Organogenesis Holdings had revenue of $101.01M in the quarter ending June 30, 2025, a decrease of -22.44%. This brings the company's revenue in the last twelve months to $429.53M, down -4.21% year-over-year. In the year 2024, Organogenesis Holdings had annual revenue of $482.04M with 11.29% growth.
Revenue (ttm)
$429.53M
Revenue Growth
-4.21%
P/S Ratio
1.22
Revenue / Employee
$494,282
Employees
869
Market Cap
516.31M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 482.04M | 48.90M | 11.29% |
Dec 31, 2023 | 433.14M | -17.75M | -3.94% |
Dec 31, 2022 | 450.89M | -16.47M | -3.52% |
Dec 31, 2021 | 467.36M | 129.06M | 38.15% |
Dec 31, 2020 | 338.30M | 77.32M | 29.63% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ORGO News
- 4 days ago - Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO - Business Wire
- 20 days ago - Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 22 days ago - Organogenesis: Mixed ReNu Data, But Policy Tailwinds And Growth Remain Bullish - Seeking Alpha
- 25 days ago - Why Is Organogenesis Stock Trading Lower Friday? - Benzinga
- 26 days ago - Organogenesis Provides Update on Second Phase 3 ReNu® Study - GlobeNewsWire
- 7 weeks ago - Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
- 2 months ago - Organogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results - GlobeNewsWire